TICKERNERD
Menu
DSGNDSGNHealthcare · Biotechnology

DSGN Stock Forecast: Design Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$15
+3.06% on the day

The 7 Wall Street analysts covering Design Therapeutics, Inc. hold a median 12-month price target of $21 — +41.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$928.1M
Ticker Nerd rank
65 / 100
Median analyst target
$21
Analysts covering
7
Total return, dividends reinvested
1W
+6.0%
1M
+8.5%
YTD
+58.1%
1Y
+187.4%
From 52W high
−6.1%
From 52W low
+209.6%
$5
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DSGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Design Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
85
Accruals
73
Value
66
Volatility
62
Revisions
60
Quality
52
Size
46
Growth
40
Issuance
34

Momentum (85): The shares have been drifting up relative to others.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DSGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DSGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26DSGNHigh $22Median $21Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $20Median $21High $22

The green dot is the last close — the median target sits +41.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 May 2026OppenheimerMaintainsOutperform$18 → $21
16 Mar 2026JefferiesInitiatesBuy—
10 Mar 2026RBC CapitalMaintainsOutperform—
7 Jan 2026OppenheimerInitiatesOutperform—
3 Dec 2025Leerink PartnersUpgradeOutperform—
20 Nov 2025RBC CapitalUpgradeOutperform—
6 Nov 2025RBC CapitalMaintainsSector Perform—
6 Aug 2024RBC CapitalReiteratesSector Perform—
7 May 2024Piper SandlerUpgradeOverweight—
20 Mar 2024RBC CapitalReiteratesSector Perform—
20 Mar 2024WedbushReiteratesNeutral—
14 Nov 2023RBC CapitalMaintainsSector Perform—
15 Aug 2023RBC CapitalDowngradeSector Perform—
15 Aug 2023SVB LeerinkDowngradeMarket Perform—
15 Aug 2023WedbushDowngradeNeutral—
10 May 2023RBC CapitalMaintainsOutperform—
10 May 2023WedbushMaintainsOutperform—
4 May 2023Goldman SachsUpgradeNeutral—
15 Mar 2023RBC CapitalReiteratesOutperform—
9 Dec 2022SVB LeerinkMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DSGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DSGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Design Therapeutics, Inc. (DSGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.1×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
4.6×

Cheaper than 24% of US stocks

EV / EBITDA
−9.2×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−34.1%

Higher than 26% of US stocks

Return on assets
−22.5%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DSGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DSGNDesign Therapeutics, Inc.$928.1M
65
ABUSArbutus Biopharma Corp.$919.7M
96
OLMAOlema Pharmaceuticals, Inc.$926.5M
29
CLYMClimb Bio, Inc.$935.1M
61
GERNGeron Corp.$941.6M
52
SGPSpyGlass Pharma, Inc.$872.9M
1
KURAKura Oncology, Inc.$964.0M
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Design Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DSGN news & analysis

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 3 Aug 2026positive

Design Therapeutics announced modifications to its RESTORE-FA clinical trial based on positive four-week data, expects 12-week dosing data in Q1 2027, initiated dosing in a Phase 1 trial of DT-818 for myotonic dystrophy type 1, and reported $207.4 million in cash and securities at the end of Q2 2026.

Why it matters — The update provides a clearer timeline for key data readouts from the RESTORE-FA trial and shows advancement of another pipeline candidate, DT-818, into clinical development.

FAQ

Frequently asked questions about DSGN stock

What is the DSGN stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Design Therapeutics, Inc. have a median 12-month price target of $21, with estimates ranging from $20 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DSGN stock a buy right now?

Of the 7 analysts covering Design Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Design Therapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DSGN?

As at 15 Aug 2026, Design Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (85 of 100).

Will DSGN stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +41.6% from the last close, and Ticker Nerd's factor model ranks Design Therapeutics, Inc. 65 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DSGN stock forecast for 2030?

No analyst covering Design Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DSGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $22 over the next 12 months.

How has DSGN stock performed over the past year?

Design Therapeutics, Inc. returned +187.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Design Therapeutics, Inc. do?

Design Therapeutics Inc. is a biotechnology company focused on developing treatments for serious degenerative disorders.

What is the latest news on DSGN?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results". Design Therapeutics announced modifications to its RESTORE-FA clinical trial based on positive four-week data, expects 12-week dosing data in Q1 2027, initiated dosing in a Phase 1 trial of DT-818 for myotonic dystrophy type 1, and reported $207.4 million in cash and securities at the end of Q2 2026.

Company

About Design Therapeutics, Inc.

Design Therapeutics Inc. is a biotechnology company focused on developing treatments for serious degenerative disorders. At the heart of its operations is the use of a proprietary technology platform aimed at addressing the underlying genetic causes of such conditions. Design Therapeutics specializes in creating what they call GeneTAC™ molecules, which are designed to target and modulate the transcription of dysfunctional genes within the human genome. This innovative approach is primarily tailored towards combatting inherited diseases linked to gene expression dysregulation. The company's efforts predominantly impact the health sector, specifically targeting rare genetic and neurological diseases. Founded to bridge the gap between cutting-edge genetic research and clinical application, Design Therapeutics strives to bring new therapeutic options to patients with limited treatment choices. By integrating advancements in gene expression modulation, the company plays a vital role in advancing biotechnology solutions and broadening the scope of personalized medicine.

CEO Mr. Pratik Shah Ph.D. · 55 employees · United States · https://www.designtx.com